Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Conditions:   Metastatic Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Metastatic Nasopharyngeal Undifferentiated Carcinoma;   Nasopharyngeal Nonkeratinizing Carcinoma;   Recurrent Nasopharyngeal Carcinoma;   Recurrent Nasopharyngeal Keratinizing Squa mous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Carcinoma AJCC v8;   Stage IVA Nasopharyngeal Carcinoma AJCC v8;   Stage IVB Nasopharyngeal Carcinoma AJCC v8 Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Gemcitabine;   Biological: Nivolumab;   Other: Questionnaire Administration Sponsors:   National Cancer Institute (NCI);   NRG Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials